DD-723 Phase II clinical trial (Breast)
Phase 2
- Conditions
- Patients with breast tumor
- Registration Number
- JPRN-jRCT2080220863
- Lead Sponsor
- DAIICHISANKYO Co.,Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Patients with focal breast tumor
- Patients scheduled to undergo pathological examination
- Patients aged between 20 and 80 years at the time of informed consent
Exclusion Criteria
- Items listed on the package insert (including absolute contraindications, careful administration, and precautions) to ensure safety.
- Items related to safety and ethics
- Items related to surgery, procedures, and treatment that are considered to influence efficacy and safety assessment for this drug
- Patients who are pregnant, possibly, pregnant, or lactating
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effectiveness of contrast effect
- Secondary Outcome Measures
Name Time Method Right diagnosis between benign and malignant tumor, assessment of tumor extent